Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma ...

“Based on these robust data, and our recent End-of-Phase 1 meeting with the FDA, we have initiated PiNACLE, a single-arm pivotal trial of LYL314 in patients with large B-cell lymphoma in the third- or ...

Investigators confirmed the safety and efficacy outcomes of a total of 3 CD19-directed chimeric antigen receptor (CAR) T-cell therapies with other real-world data with CAR T-cell therapy in patients ...

“Liso-cel achieved high, lasting response rates in patients with relapsed or refractory marginal zone lymphoma, underscoring the potential of this one-time therapy to significantly improve patient ...

Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ...

Genmab A/S today announced new results from the Phase 1 b/2 EPCORE ® NHL-2 trial Arm 10, evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination ...

Johnson & Johnson said the first clinical data from its ongoing Phase 1b study of JNJ-4496, a chimeric antigen receptor T-cell therapy, shows encouraging potential in treating large B-cell ...

Claudin-18 isoform 2 (CLDN18.2) has emerged as a promising therapeutic target in gastric or gastro-oesophageal junction cancer. Satricabtagene autoleucel (satri-cel; also known as CT041), an ...

Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) usually receive a covalent Bruton tyrosine kinase inhibitor (cBTKi) as part of their first-line or second-line therapy ...

Mantle cell lymphoma (MCL) is an aggressive, incurable B-cell lymphoma. 1-3 Chemoimmunotherapy typically followed by autologous stem-cell transplant has been the standard of care in young, fit ...

Among patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), Columvi (glofitamab) plus chemotherapy with gemcitabine and oxaliplatin (GemOx) demonstrated enhanced survival outcomes ...